期刊文献+

唑来膦酸治疗恶性肿瘤骨转移引起疼痛的疗效分析 被引量:12

Clinical effect of zoletronic acid for pain caused by bone metastasis
下载PDF
导出
摘要 为了探讨唑来膦酸治疗骨转移引起疼痛的效果和不良反应,将恶性肿瘤骨转移引起疼痛的160例患者分为2组,治疗组78例,采用唑来膦酸4mg静脉滴入(15min以上),每4周重复1次;对照组82例采用帕米膦酸钠90mg静脉滴入6h,每4周重复1次。结果提示疼痛缓解总有效率在治疗组、对照组各为92.3%和82.9%,P=0.073。疼痛缓解后复发时间,治疗组和对照组各为16.4、12.6d,P=0.184;两组不良反应轻微,对照组发热发生率略高于治疗组。初步研究结果提示,唑来膦酸对骨转移引起的疼痛有良好的止痛效果,不良反应少。 The objective of this study was to evaluate the clinical efficacy and side effect of zoletronic acid for bone metastasis of malignance neoplasms. A total of 160 cases with bone pain of bone mallgnance metastasis were divided into two groups. In the treatment group, 78 patients received zoletronic acid (4 mg i. v. , 15 minutes, every 4 weeks). In the control group, 82 patients received pamidronate (90 mg i. v. , 6 hours, every 4 weeks). Results:Response rates of bone pain relief were 92.3% and 82.9% respectively in the zoletronic acid group and in the pamidronate group,P=0. 073. The time from relief to relapse was 16.4 days or 12.6 days in the zoletronic acid group and in the pamidronate group, respectively P=0. 184. The side effect was gentle in both groups. The Fever Percentage was found in the pamidronate group higher than in the zoletronic acid group. In conclusion, zoletronic acid can relive bone pain of metastasis effectively with little side effect.
出处 《中华肿瘤防治杂志》 CAS 2006年第12期949-950,共2页 Chinese Journal of Cancer Prevention and Treatment
关键词 唑来膦酸 帕米膦酸二钠 骨转移 骨痛 治疗 zoletronic acid pamidronate bone metastasis bone pain therapy
  • 相关文献

参考文献7

  • 1刘瑶,刘治军,傅得兴.新一代二膦酸盐类药物唑来膦酸的药理及临床[J].中国新药杂志,2004,13(11):1058-1060. 被引量:11
  • 2Manikandan R,Mistry R,Philip J,et al.Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers[J].BJU Int,2006,9,7(3):653.
  • 3Delea T,Langer C,McKiernan J,et al.The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer[J].Oncology,2004,67 (5-6):390-396.
  • 4Corso A,Ferretti E,Lunghi M,et al.Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma:a possible mechanism for its antitumor effect[J].Cancer,2005,104(1):118-125.
  • 5Leto G,Badalamenti G,Arcara C,et al.Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases[J].Anticancer Res,2006,26 (1A):23-26.
  • 6Mystakidou K,Katsouda E,Parpa E,et al.Randomized,open label,prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline[J].Med Oncol,2005,22(2):195-201.
  • 7Tanvetyanon T,Hines E Jr.Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors[J].Cancer,2004,100(12):2613-2621.

二级参考文献12

  • 1[1]Evdokiou A,Labrinidis A.Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis[J].Bone,2003,33(2):216-28.
  • 2[2]Neville-Webbe H,Coleman RE.The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia[J].Palliat Med,2003,17(6):539-553.
  • 3[3]Witters LM,Crispino J.Effect of the combination of docetaxel,zoledronic acid,and a COX-2 inhibitor on the growth of human breast cancer cell lines[J].Am J Clin Oncol,2003,26(4):92-97.
  • 4[4]Jagdev SP,Croucher PI,Coleman RE.Zoledronate induces apoptosis of breast cancer cells in vitro evidence for additive and synergistic effects with taxol and tamoxifen[J].Proc Am Soc Clin Oncol,2000,19(6):664a.
  • 5[5]Tassone P,Forciniti S,Galea E,et al.Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines[J].Leukemia,2000,14(3):841-844.
  • 6[6]Chen T,Berenson J.Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases[J].J Clin Pharmacol,2002,42(11):1228-1236.
  • 7[7]Skerjance A,Berenson J.The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function[J].J Clin Pharmacol,2003,43(2):154-162.
  • 8[8]Lipton A,Zheng M,Seaman J,et al.Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma[J].Cancer,2003,98(5):962-969.
  • 9[9]Smith MR,Eastham J,Gleason DM.Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer[J].J Urol,2003,169(6):2008-2012.
  • 10[10]Rosen LS,Gordon D,Tchekmedyian S,et al.Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors[J].J Clin Oncol,2003,21(16):3150-3157.

共引文献10

同被引文献134

引证文献12

二级引证文献89

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部